Vapotherm, Inc. (VAPO): Price and Financial Metrics

Vapotherm, Inc. (VAPO): $2.38

0.15 (-5.93%)

POWR Rating

Component Grades








Add VAPO to Watchlist
Sign Up

Industry: Medical - Consumer Goods




#8 of 10

in industry

VAPO Price/Volume Stats

Current price $2.38 52-week high $23.65
Prev. close $2.53 52-week low $2.20
Day low $2.32 Volume 26,500
Day high $2.48 Avg. volume 36,905
50-day MA $3.09 Dividend yield N/A
200-day MA $6.38 Market Cap 14.60M

VAPO Stock Price Chart Interactive Chart >


  • Growth is the dimension where VAPO ranks best; there it ranks ahead of 94.38% of US stocks.
  • VAPO's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • VAPO's current lowest rank is in the Momentum metric (where it is better than 6.97% of US stocks).

VAPO Stock Summary

  • VAPO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.73% of US stocks.
  • The volatility of VAPOTHERM INC's share price is greater than that of 97.61% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VAPO comes in at -147.06% -- higher than that of just 3.99% of stocks in our set.
  • Stocks that are quantitatively similar to VAPO, based on their financial statements, market capitalization, and price volatility, are OTRK, APPS, PHUN, SONX, and MNKD.
  • Visit VAPO's SEC page to see the company's official filings. To visit the company's web site, go to

VAPO Valuation Summary

  • In comparison to the median Healthcare stock, VAPO's EV/EBIT ratio is 112.93% lower, now standing at -1.5.
  • VAPO's price/sales ratio has moved down 6.3 over the prior 59 months.

Below are key valuation metrics over time for VAPO.

Stock Date P/S P/B P/E EV/EBIT
VAPO 2023-09-22 0.2 -0.4 -0.2 -1.5
VAPO 2023-09-21 0.3 -0.5 -0.2 -1.5
VAPO 2023-09-20 0.3 -0.5 -0.2 -1.6
VAPO 2023-09-19 0.3 -0.6 -0.2 -1.6
VAPO 2023-09-18 0.3 -0.6 -0.2 -1.6
VAPO 2023-09-15 0.3 -0.6 -0.3 -1.6

VAPO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VAPO has a Quality Grade of F, ranking ahead of 3.49% of graded US stocks.
  • VAPO's asset turnover comes in at 0.702 -- ranking 53rd of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows VAPO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.702 0.501 -0.633
2021-06-30 0.636 0.505 -0.633
2021-03-31 0.680 0.511 -0.536
2020-12-31 0.688 0.501 -0.623
2020-09-30 0.624 0.493 -0.583
2020-06-30 0.572 0.480 -0.610

Vapotherm, Inc. (VAPO) Company Bio

Vapotherm Inc. Vapotherm, Inc. is a global medical technology company. The Company is focused on the development and commercialization of its high velocity nasal insufflations (Hi-VNI) technology products that are used to treat patients suffering from respiratory distress. Its Hi-VNI technology delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Its Precision Flow systems uses its Hi-VNI technology. It offers three versions of its Precision Flow systems: Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its Precision Flow versions are integrated systems that provide precise user control of temperature, air flow and percentage oxygen through a one-button interface.

VAPO Latest News Stream

Event/Time News Detail
Loading, please wait...

VAPO Latest Social Stream

Loading social stream, please wait...

View Full VAPO Social Stream

Latest VAPO News From Around the Web

Below are the latest news stories about VAPOTHERM INC that investors may wish to consider to help them evaluate VAPO as an investment opportunity.

Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children

EXETER, N.H., September 25, 2023--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the presentation of an Investigator-initiated clinical trial, "High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility randomized controlled

Yahoo | September 25, 2023

Insider Buying: Vapotherm Inc's President and CEO Joseph Army Acquires 100,000 Shares

On September 8, 2023, Joseph Army, President and CEO of Vapotherm Inc (NYSE:VAPO), purchased 100,000 shares of the company, marking a significant insider buying activity.

Yahoo | September 12, 2023

Vapotherm (VAPO) Reports Q2 Loss, Misses Revenue Estimates

Vapotherm (VAPO) delivered earnings and revenue surprises of 23.68% and 4.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 8, 2023

Vapotherm Reports Second Quarter 2023 Financial Results

EXETER, N.H., August 08, 2023--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2023 financial results.

Yahoo | August 8, 2023

Vapotherm To Report Second Quarter 2023 Financial Results

EXETER, N.H., July 25, 2023--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.

Yahoo | July 25, 2023

Read More 'VAPO' Stories Here

VAPO Price Returns

1-mo -22.98%
3-mo -22.55%
6-mo -54.92%
1-year -81.97%
3-year -98.91%
5-year N/A
YTD -88.98%
2022 -86.96%
2021 -22.90%
2020 120.89%
2019 -39.05%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!